Arisaph's strong medicinal chemistry expertise and the Company's proprietary drug discovery platforms represent important assets for the Company that can be maximized through drug discovery partnerships, research collaborations, out-licensing or co-development partnerships. In addition, Arisaph seeks to augment its product pipeline and to access complementary research, technology and development capabilities through in-licensing. The Company’s business development strategy seeks to leverage these assets through the following mechanisms:
1. Drug Discovery Partnerships.
In these partnerships, Arisaph discovers and designs new compounds that address select and validated targets and the partner screens such compounds for proof-of-concept efficacy. In this manner, Arisaph is able to leverage its competencies in an extremely focused manner without having to conduct significant basic research to identify a target, which is often time-consuming, expensive and risky. Moreover, this partnership strategy also expands Arisaph’s therapeutic field and will help fuel the growth of the Company.
2. Research Collaborations.
In establishing the differentiated attributes of various drug candidates that Arisaph is developing internally, the Company often forms collaborations with academic or research institutions. In such collaborations, Arisaph utilizes its drug discovery capabilities to design differentiated drug candidates and the research institution screens such compounds for effectiveness on appropriate targets. Once viable lead candidates are identified, Arisaph progresses the development of the compound on its own or through co-development partnerships or direct out-licensing.
3. Out-licensing or Co-development Partnerships.
Possessing important data that demonstrates the viability of a lead candidate, Arisaph also explores the possibility of out-licensing or co-developing viable drug candidates that the Company has discovered internally. Such strategy uses the partner’s skills and resources to conduct time-consuming and expensive clinical studies, while Arisaph participates in the expected value creation through anticipated royalty and milestone payments.
While Arisaph prides itself on its drug discovery abilities, we also recognize our efforts are limited to the infinite possibilities that healthcare offers. Accordingly, partnering is an essential component of our strategy to developing novel medicines addressing unmet medical needs.